We specialise in bridging the gap between small-scale synthesis and large-scale production, accelerating drug discovery and development with cutting-edge expertise. Our seamless scale-up capabilities, advanced purification techniques and innovative reaction methodologies ensure efficiency and high-quality outcomes. Beyond small molecules, we support emerging therapeutic modalities like like proteolysis targeting chimeras (PROTAC®s), antibody-drug-conjugates (ADCs) and peptides, offering expertise in linker design, bioavailability and structure-activity optimisation. Our physicochemical characterisation services further enhance drug developability, integrating data-driven insights to drive smarter, faster decisions.